Streptokinase
|
Complex of catalytic domain of human plasmin and streptokinase
|
| Clinical data |
| AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
Pregnancy
category |
- US: C (Risk not ruled out)
|
Routes of
administration |
intravenous |
| ATC code |
|
| Identifiers |
| CAS Number |
|
| DrugBank |
|
| ChemSpider |
|
| ECHA InfoCard |
100.029.667 |
| Chemical and physical data |
| Formula |
C2100H3278N566O669S4 |
| Molar mass |
47,286.7 |
Streptokinase (SK) is a thrombolytic medication and enzyme.[1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism.[2] The type of heart attack it is used in is an ST elevation myocardial infarction (STEMI).[3] It is used by injection into a vein.[2]
Side effects include nausea, bleeding, low blood pressure, and allergic reactions.[2] A second use in a person's lifetime is not recommended.[2] While no harm has been found with use in pregnancy, it has not been well studied in this group.[4] Streptokinase is in the antithrombotic family of medications and works by turning on the fibrinolytic system.[3]
Streptokinase was discovered in 1933 from Beta hemolytic streptococci.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[5] The wholesale cost is between 30.00 and 138.00 USD per dose as of 2014.[6] It is no longer commercially available in the United States.[7]
Contents
- 1 Medical uses
- 2 Contraindications
- 2.1 Absolute
- 2.2 Relative
- 3 Mechanism of action
- 4 History
- 5 Research
- 6 Marketing
- 7 References
Medical uses
If percutaneous coronary intervention (PCI) is not available within 90-120 minutes of first contact, streptokinase is recommended intravenously as soon as possible after the onset of a ST elevation myocardial infarction (STEMI). As Streptokinase is a bacterial product, the body has the ability to build up an immunity to it. Therefore, it is recommended that this medication should not be used again after four days from the first administration, as it may not be as effective and can also cause an allergic reaction. For this reason, it is usually given only for a person's first heart attack. Further thrombotic events could be treated with Tissue plasminogen activator (tPA). Overdose of streptokinase or tPA can be treated with aminocaproic acid.
Contraindications
Absolute
- Any prior intracranial hemorrhage
- Known structural cerebral vascular lesion (eg, arteriovenous malformation)
- Known cancer inside the skull (primary or metastatic)
- Ischemic stroke more than 4.5 hours and less than 3 months ago
- Suspected aortic dissection
- Active bleeding or bleeding problem other than menstruation
- Significant closed-head or facial trauma within 3 months
- Intracranial or intraspinal surgery within 2 months
- Severe uncontrolled high blood pressure (unresponsive to emergency therapy)
- For streptokinase, prior treatment within the previous 6 months
Relative
- History of chronic, severe, poorly controlled hypertension
- Significant hypertension on presentation (SBP >180 mm Hg or DBP >110 mm Hg)
- History of prior ischemic stroke more than 3 month ago
- Dementia
- Known intracranial pathology not covered in absolute contraindications
- Traumatic or prolonged (>10 min) CPR
- Major surgery less than three weeks ago
- Recent (within 2 to 4 wk) internal bleeding
- Noncompressible vascular punctures
- Pregnancy
- Active peptic ulcer
- Oral anticoagulant therapy
[8]
Mechanism of action
| Streptokinase C |
| Identifiers |
| Symbol |
skc |
| Entrez |
8110746 |
| PDB |
1BML |
| UniProt |
P00779 |
| Other data |
| EC number |
3.4.24.29 |
| Staphylokinase/Streptokinase family |
|
Structure of staphylokinase, a plasminogen activator.[9]
|
| Identifiers |
| Symbol |
Staphylokinase |
| Pfam |
PF02821 |
| InterPro |
IPR004093 |
| SCOP |
2sak |
| SUPERFAMILY |
2sak |
| Available protein structures: |
| Pfam |
structures |
| PDB |
RCSB PDB; PDBe; PDBj |
| PDBsum |
structure summary |
|
Proposed counterion for Asp740 is Lys698 create salt-bridge
Substrate Enzyme Mechanism Movie
Streptokinase belongs to a group of medications known as fibrinolytics, and complexes of streptokinase with human plasminogen can hydrolytically activate other unbound plasminogen by activating through bond cleavage to produce plasmin. There are three domains to streptokinase, denoted α (residues 1–150), β (residues 151–287), and γ (residues 288–414). Each domain binds plasminogen, although none can activate plasminogen independently.[10]
Plasmin is produced in the blood to break down fibrin, the major constituent of blood thrombi, thereby dissolving clots once they have fulfilled their purpose of stopping bleeding. Extra production of plasmin caused by streptokinase breaks down unwanted blood clots, for example, in the lungs (pulmonary embolism). The usual activation of Plasminogen (Plgn) is by proteolysis of the Arg561—Val562 bond.[11] The amino group of Val562 then forms a salt-bridge with Asp740, which triggers a conformational change producing the active protease Plasmin (Pm). When (SK) is present, it binds to Plgn to form a complex (SK. Plgn) that converts substrate Plgn to Pm. Residues 1–59 of SK regulate its capacity to induce an active site in bound Pg by a nonproteolytic mechanism and to activate substrate Pg in a fibrin-independent manner. This complex subsequently rearranges to an active complex although the Arg561–Val562 bond remains intact. Therefore, another residue must substitute for the free amino group of Val562 and provide a counterion for Asp740 in this active complex.[12] Two candidates for this counterion have been suggested: Ile1 of streptokinase and Lys698 of Plgn. Deletion of Ile1 of SK markedly inhibits its capacity to induce an active site in plasminogen, which supports the hypothesis that establishment of a salt bridge between Ile1 of SK and Asp740 of plasminogen is necessary for SK to induce an active site in plasminogen by a nonproteolytic mechanism.[13] In contrast with the Ile1 substitutions, the Lys698 mutations also decreased the dissociation constant of the SK complex by 15 to 50 fold. These observations suggest that Lys698 is involved in formation of the initial SK·Plgn complex.[14]
History
After many years of work along with his student Sol Sherry, William Smith Tillett founded it in 1933. Initially used in treatment of fibrinous pleural exudates, hemothorax and tuberculous meningitis. Its role in acute myocardial infarction was serendipitous.[15] It was later named as streptokinase.
Research
Streptokinase may find a use in helping to prevent postoperative adhesions, a common complication of surgery, especially abdominal surgery (appendectomy, gall stones, hysterectomy, etc.) One study using animal models (rats) found that when used with a PHBV membrane drug-delivery system, it was 90 percent effective in preventing adhesions.[16] However, it has not been shown to be effective in humans in a clinical trial.
Marketing
It is marketed in Chile as Streptase by Alpes Selection, under license of CSL Behring Germany.
Available in Viet Nam under the name Mutose. Available in Cuba, Venezuela, Ecuador and other Latin American countries under the trademark Heberkinasa, commercialized by Heber Biotech, Havana, Cuba. Available in India under the name STPase by Cadila Pharmaceuticals, and Myokinase by Biocon Limited.
References
- ^ a b Sikri N, Bardia A (2007). "A history of streptokinase use in acute myocardial infarction". Texas Heart Institute Journal. 34 (3): 318–27. PMC 1995058 . PMID 17948083.
- ^ a b c d WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 291-292. ISBN 9789241547659. Retrieved 8 December 2016.
- ^ a b "Streptokinase 1,500,000 iu - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. 1 July 2015. Retrieved 14 December 2016.
- ^ "Streptokinase Use During Pregnancy | Drugs.com". www.drugs.com. Retrieved 14 December 2016.
- ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- ^ "Streptokinase". International Drug Price Indicator Guide. Retrieved 28 November 2015.
- ^ "streptokinase (Intravenous route, Intracoronary route)". Truven Health Analytics. Retrieved 28 November 2015.
- ^ O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. (2013). "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 127 (4): e362–425. PMID 23247304. doi:10.1161/CIR.0b013e3182742cf6.
- ^ Rabijns A, De Bondt HL, De Ranter C (May 1997). "Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential". Nature Structural Biology. 4 (5): 357–60. PMID 9145104. doi:10.1038/nsb0597-357.
- ^ Mundada LV, Prorok M, DeFord ME, Figuera M, Castellino FJ, Fay WP (July 2003). "Structure-function analysis of the streptokinase amino terminus (residues 1-59)". The Journal of Biological Chemistry. 278 (27): 24421–7. PMID 12704199. doi:10.1074/jbc.M301825200.
- ^ Young KC, Shi GY, Wu DH, Chang LC, Chang BI, Ou CP, Wu HL (January 1998). "Plasminogen activation by streptokinase via a unique mechanism". The Journal of Biological Chemistry. 273 (5): 3110–6. PMID 9446629. doi:10.1074/jbc.273.5.3110.
- ^ Loy JA, Lin X, Schenone M, Castellino FJ, Zhang XC, Tang J (December 2001). "Domain interactions between streptokinase and human plasminogen". Biochemistry. 40 (48): 14686–95. PMID 11724583. doi:10.1021/bi011309d.
- ^ Wang S, Reed GL, Hedstrom L (April 1999). "Deletion of Ile1 changes the mechanism of streptokinase: evidence for the molecular sexuality hypothesis". Biochemistry. 38 (16): 5232–40. PMID 10213631. doi:10.1021/bi981915h.
- ^ Wang X, Lin X, Loy JA, Tang J, Zhang XC (September 1998). "Crystal structure of the catalytic domain of human plasmin complexed with streptokinase". Science. 281 (5383): 1662–5. PMID 9733510. doi:10.1126/science.281.5383.1662.
- ^ Sikri N, Bardia A (2007). "A history of streptokinase use in acute myocardial infarction". Texas Heart Institute Journal. 34 (3): 318–27. PMC 1995058 . PMID 17948083.
- ^ Yagmurlu A, Barlas M, Gursel I, Gokcora IH (2003). "Reduction of surgery-induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system". European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes. 35 (1): 46–9. PMID 12566787. doi:10.1159/000067035.
|
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
| Antiplatelet drugs |
| Glycoprotein IIb/IIIa inhibitors |
- Abciximab
- Eptifibatide
- Orbofiban
- Roxifiban
- Sibrafiban§
- Tirofiban
|
| ADP receptor/P2Y12 inhibitors |
- Thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- Nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
| Prostaglandin analogue (PGI2) |
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
| COX inhibitors |
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
| Thromboxane inhibitors |
- Thromboxane synthase inhibitors
- Dipyridamole (+ aspirin)
- Picotamide
- Terbogrel
- Receptor antagonists
|
| Phosphodiesterase inhibitors |
- Cilostazol
- Dipyridamole
- Triflusal
|
| Other |
- Cloricromen
- Ditazole
- Vorapaxar
|
|
| Anticoagulants |
Vitamin K antagonists
(inhibit II, VII, IX, X) |
- Coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- Other: Tioclomarol
|
Factor Xa inhibitors
(with some II inhibition) |
Heparin group/
glycosaminoglycans/
(bind antithrombin) |
- Low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin‡
- Oligosaccharides
- Fondaparinux
- Idraparinux§
- Heparinoids
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
| Direct Xa inhibitors ("xabans") |
- Apixaban
- Betrixaban
- Darexaban§
- Edoxaban
- Otamixaban§
- Rivaroxaban
|
|
| Direct thrombin (IIa) inhibitors |
- Bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- Univalent: Argatroban
- Dabigatran
- Efegatran
- Inogatran§
- Melagatran‡
- Ximelagatran‡
|
| Other |
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
Thrombolytic drugs/
fibrinolytics |
- Plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- Other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
| Non-medicinal |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Endopeptidases: serine proteases/serine endopeptidases (EC 3.4.21)
|
| Digestive enzymes |
- Enteropeptidase
- Trypsin
- Chymotrypsin
- Elastase
|
| Coagulation |
- factors: Thrombin
- Factor VIIa
- Factor IXa
- Factor Xa
- Factor XIa
- Factor XIIa
- Kallikrein
- PSA
- KLK1
- KLK2
- KLK3
- KLK4
- KLK5
- KLK6
- KLK7
- KLK8
- KLK9
- KLK10
- KLK11
- KLK12
- KLK13
- KLK14
- KLK15
- fibrinolysis: Plasmin
- Plasminogen activator
- Tissue plasminogen activator
- Urinary plasminogen activator
|
| Complement system |
- Factor B
- Factor D
- Factor I
- MASP
- C3-convertase
|
| Other immune system |
- Chymase
- Granzyme
- Tryptase
- Proteinase 3/Myeloblastin
|
| Venombin |
|
| Other |
- Acrosin
- Prolyl endopeptidase
- Pronase
- Proprotein convertases
- Prostasin
- Reelin
- Subtilisin/Furin
- Streptokinase
- S1P
- Cathepsin
|
